Davis C.N, Rock K.S, Antillón M, Miaka E.M, Keeling M.J. Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo. BMC Med. 2021;19:86. DOI: 10.1186/s12916-021-01943-4

2021
Journal Article
PubMed (33794881)
Link

Baral R, Li X, Willem L, Antillon M, Vilajeliu A, Jit M, Beutels P, Pecenka C. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: estimates from two models. Vaccine. 2020;38(33):5139-5147. DOI: 10.1016/j.vaccine.2020.06.036

2020
Journal Article
PubMed (32586761)
Link

Leuba S.I, Yaesoubi R, Antillon M, Cohen T, Zimmer C. Tracking and predicting U.S. influenza activity with a real-time surveillance network. PLoS Comput Biol. 2020;16(11):e1008180. DOI: 10.1371/journal.pcbi.1008180

2020
Journal Article
PubMed (33137088)
Link

Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18(1):82. DOI: 10.1186/s12916-020-01537-6

2020
Journal Article
PubMed (32248817)
Link

NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis. Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT). Gates Open Res. 2020;3:1553. DOI: 10.12688/gatesopenres.13070.1

2020
Journal Item
Link